4‐nitrobenzoate inhibits 4‐hydroxybenzoate polyprenyltransferase in malaria parasites and enhances atovaquone efficacy
FEBS Letters · 2026
DOI: 10.1002/1873-3468.70186 ↗Kurz gefasst
Fachartikel in der Zeitschrift FEBS Letters, 2026. Verfasst von Ignasi Bofill Verdaguer und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Parasitology, Institute of Biomedical Sciences, University of São Paulo, Brazil. Hauptthemen laut MEDLINE: Atovaquone, Plasmodium falciparum, Antimalarials, Parabens. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação de Amparo Pesquisa do Estado de São Paulo, Fundação de Amparo à Pesquisa do Estado de São Paulo.
Abstract (Originalsprache)
Ubiquinone (UQ) is essential for the electron transport chain in Plasmodium falciparum , the causative agent of severe malaria. Its biosynthesis begins with the condensation of 4‐hydroxybenzoate (4‐HB) and an isoprenoid chain, catalyzed by 4‐HB polyprenyltransferase (4‐HPT; COQ2 gene). Atovaquone (AV) inhibits the mitochondrial bc1 complex by competing with ubiquinol (UQH 2 ), but resistance to the synergic combination AV/proguanil therapy has emerged. Here, we show that 4‐nitrobenzoate (4‐NB) inhibits Pf 4‐HPT, enhances AV efficacy and selectivity, while preserving proguanil synergy. In Saccharomyces cerevisiae expressing PfCOQ2 , 4‐NB inhibited UQ biosynthesis. In vivo , 4‐NB improved AV efficacy in Plasmodium berghei ‐infected mice. Structure–activity studies with 4‐HB analogs further defined chemical features for potentiation. These findings support PfCOQ2 as a target to boost AV‐based antimalarial therapy. Impact statement This study identifies a molecular rationale for enhancing atovaquone efficacy through targeted inhibition of ubiquinone biosynthesis. By validating PfCOQ2 as a druggable target and demonstrating in vivo potentiation, our findings offer strategic advance toward rational antimalarial combination therapies, moving beyond empirical approaches and addressing current resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Parasitology, Institute of Biomedical Sciences, University of São Paulo, Brazil.
- Betternostics S.L., Noain, Navarre, Spain.
- Department of Clinical and Toxicological Analysis, School of Pharmaceutical Sciences, Federal University of Alfenas, Brazil.
ORCID-Profile: Ignasi Bofill Verdaguer, Alejandro Miguel Katzin, Marcell Crispim
Förderung
- Fundação de Amparo Pesquisa do Estado de São Paulo
- Fundação de Amparo à Pesquisa do Estado de São Paulo
Zitieren
APA
Verdaguer, I. B., Santos, M. F., Filho, M. M., Castro, G. O., Hernández, A., Peres, M. A., Katzin, A. M., & Crispim, M. (2026). 4‐nitrobenzoate inhibits 4‐hydroxybenzoate polyprenyltransferase in malaria parasites and enhances atovaquone efficacy. FEBS Letters. https://doi.org/10.1002/1873-3468.70186
Vancouver
Verdaguer IB, Santos MF, Filho MM, Castro GO, Hernández A, Peres MA, et al. 4‐nitrobenzoate inhibits 4‐hydroxybenzoate polyprenyltransferase in malaria parasites and enhances atovaquone efficacy. FEBS Letters. 2026. doi:10.1002/1873-3468.70186
BibTeX
@article{Verdaguer2026,
author = {Verdaguer, Ignasi Bofill and Santos, Matheus Felipe and Filho, Maurício Mazzine and Castro, Gabriela Oliveira and Hernández, Agustín and Peres, Manoel Aparecido and Katzin, Alejandro Miguel and Crispim, Marcell},
title = {4‐nitrobenzoate inhibits 4‐hydroxybenzoate polyprenyltransferase in malaria parasites and enhances atovaquone efficacy},
journal = {FEBS Letters},
year = {2026},
doi = {10.1002/1873-3468.70186}
}
EUVIMED